American Portfolios Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

American Portfolios Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50	Closed	-$235	–	3131
2020 Q3	$235	Hold	50	–	–	﹤0.01%	2890
2020 Q2	$305	Sell	50 -300	-86%	-$1.24K	﹤0.01%	2787
2020 Q1	$795	Buy	350 +200	+133%	+$849	﹤0.01%	2597
2019 Q4	$689	Hold	150	–	–	﹤0.01%	2725
2019 Q3	$581	Hold	150	–	–	﹤0.01%	2699
2019 Q2	$905	Sell	150 -100	-40%	-$956	﹤0.01%	2597
2019 Q1	$3.35K	Hold	250	–	–	﹤0.01%	2221
2018 Q4	$2.33K	Hold	250	–	–	﹤0.01%	2101
2018 Q3	$3.48K	Hold	250	–	–	﹤0.01%	2110
2018 Q2	$3.95K	Hold	250	–	–	﹤0.01%	2054
2018 Q1	$4.29K	Buy	+250	New	+$4.88K	﹤0.01%	1925

Other funds holding FPRX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Portfolios Advisors's FPRX Position: Q4 2020 in Review

American Portfolios Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 50 shares — an estimated $235 sold.

American Portfolios Advisors first reported a position in FPRX in Q1 2018 and held it in 11 quarters. The position peaked at $4.29K in Q1 2018. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

American Portfolios Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
American Portfolios Advisors sold 50 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $235.
American Portfolios Advisors first reported a position in Five Prime Therapeutics, Inc. in Q1 2018 and held it in 11 quarters.
American Portfolios Advisors's Five Prime Therapeutics, Inc. position peaked at $4.29K in Q1 2018.
125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on American Portfolios Advisors's 13F filing for Q4 2020, filed 22 Mar 2023.